CYP19A1 and cancer: Therapies that act primarily through non-cell intrinsic means, such as anti-angiogenic drugs that require physiological remodeling (e.g., bevacizumab) or endocrine therapies that indirectly target hormone receptor-positive cancers (e.g., aromatase inhibitors), are currently incompatible with this workflow.